Selected data models

You must log in to select data models for download or further analysis.

40 Search results.
Relevance Rating New first Old first

GSK Efficacy and safety of Fluticasone on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) NCT01009463 - Week 4

- 4/5/18 - 1 form, 6 itemgroups, 14 items, 1 language
Itemgroups: Subject withdrawal, Pre-Dose Vital Signs, Candidiasis examination, Electronically transferred lab data, Liver Events Assessment, Smoking Status
Study ID: 102871 Clinical Study ID: HZC102871 Study Title:HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01009463 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Veramyst,Avamys,Allermist Study Indication: Pulmonary Disease, Chronic Obstructive Documentation part: Week 4

GSK Efficacy and safety of Fluticasone on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) NCT01009463 - Week 2

- 4/5/18 - 1 form, 6 itemgroups, 14 items, 1 language
Itemgroups: Subject withdrawal, Pre-Dose Vital Signs, Candidiasis examination, Electronically transferred lab data, Liver Events Assessment, Smoking Status
Study ID: 102871 Clinical Study ID: HZC102871 Study Title:HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01009463 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Veramyst,Avamys,Allermist Study Indication: Pulmonary Disease, Chronic Obstructive Documentation part: Week 2

Unknown ECOG Lung Onstudy

- 9/20/21 - 1 form, 7 itemgroups, 42 items, 1 language
Itemgroups: ECOG clinical trial administrative data, Data amendment, Pre-Treatment Characteristics, NSCLC Disease Description, Resection Information, Baseline Abnormalities, Comments
Unknown Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=109F4E7D-3810-226A-E044-0003BA3F9857

Lung Cancer null On-Study - Director's Challenge Lung Study Clinical Data Form - 2193149v1.0 - Director's Challenge Lung Study Clinical Data Form

- 9/17/21 - 1 form, 11 itemgroups, 47 items, 1 language
Itemgroups: Enrollment Requirements, Demographics, Performance Status, Smoking History, Baseline Laboratory Studies, Lung Treatment, Lung Surgical Procedure, Lymph Node Assessment, Vital Status, Follow-Up Status, Sites of Progression or Relapse
On-study data collection for Director's Challenge Lung Study 2004. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E7FC921D-AD85-346E-E034-0003BA3F9857

Unknown ECOG Lung Onstudy CRF

- 9/20/21 - 1 form, 7 itemgroups, 42 items, 1 language
Itemgroups: ECOG clinical trial administrative data, Data amendment, Pre-Treatment Characteristics, NSCLC Disease Description, Resection Information, Baseline Abnormalities, Comments
Unknown Onstudy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=109F578D-E5FE-234C-E044-0003BA3F9857

On-Study Form Lung Cancer - SCLC

- 9/20/21 - 1 form, 8 itemgroups, 68 items, 1 language
Itemgroups: CRF Header, Pre-Treatment Characteristics , Disease Description SCLC, Prior Treatment SCLC, Prior Systemic Therapy, Prior Surgery, Prior Radiation Therapy, Comments
Phase II Consortium - Phase II Lung Cancer - SCLC On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=005B53D3-2C60-14E5-E044-0003BA3F9857

Lung Cancer NCT00946712 On-Study - Southwest Oncology Group S0819 Lung Carcinoma First Site(s) Of Progression Or Relapse Form - 2863883v1.0 - Southwest Oncology Group S0819 Lung Carcinoma First Site(s) Of Progression Or Relapse Form

- 1/9/15 - 1 form, 4 itemgroups, 17 items, 1 language
Itemgroups: Header Module, Vital Status, Progression or Relapse, Comments
Southwest Oncology Group S0819 Lung Carcinoma First Site(s) Of Progression Or Relapse Form Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=684FE956-5A8B-A7DA-E040-BB89AD432A2B

Lung Cancer null On-Study - E4599 On-Study Form - 2036140v3.0 - E4599 On-Study Form

- 9/20/21 - 1 form, 1 itemgroup, 46 items, 1 language
Itemgroup: On-study form
E4599 On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A1346A5B-91C6-6A0E-E034-080020C9C0E0

On-Study - Lung Cancer - SCLC Extensive On-Study Form - 2262596v3.0 - Lung Cancer - SCLC Extensive On-Study Form

- 9/17/21 - 1 form, 5 itemgroups, 27 items, 1 language
Itemgroups: CRF Header, Lung: Pre-Treatment Characteristics, Lung: Disease Description - SCLC, Lung: Prior Treatment - Extensive SCLC, Comments
Lung Cancer - SCLC Extensive On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DE33769F-8545-3C96-E034-0003BA12F5E7

On-Study - Lung Cancer - SCLC Limited On-Study Form - 2262564v3.0 - Lung Cancer - SCLC Limited On-Study Form

- 9/17/21 - 1 form, 5 itemgroups, 27 items, 1 language
Itemgroups: CRF Header, Lung: Pre-Treatment Characteristics, Lung: Disease Description - Limited SCLC, Lung: Prior Treatment - Limited SCLC, Comments
Lung Cancer - SCLC Limited On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DE32845E-1DA8-3D2D-E034-0003BA12F5E7

On-Study - Lung Cancer - NSCLC Advanced On-Study Form - 2263427v3.0 - Lung Cancer - NSCLC Advanced On-Study Form

- 9/17/21 - 1 form, 5 itemgroups, 30 items, 1 language
Itemgroups: CRF Header, Lung: Pre-Treatment Characteristics, Lung: Disease Description - NSCLC Advanced, Lung: Prior Treatment - NSCLC Advanced, Comments
Lung Cancer - NSCLC Advanced On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DE93D710-5D45-22F0-E034-0003BA12F5E7

On-Study - Lung Cancer - SCLC Second Line On-Study Form - 2262433v3.0 - Lung Cancer - SCLC Second Line On-Study Form

- 9/17/21 - 1 form, 5 itemgroups, 33 items, 1 language
Itemgroups: CRF Header, Lung: Pre-Treatment Characteristics, Lung: Disease Description - SCLC, Lung: Prior Treatment - 2nd Line, Comments
Lung Cancer - SCLC Second Line On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DE3366B5-6F98-3BBE-E034-0003BA12F5E7

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial